Skip to content
Tuesday 11 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,862.50
-0.35%
DAX
26,323.88
0.00%
CAC 40
8,726.03
0.00%
STOXX 50
6,535.62
0.00%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

GSK

  • GSK granted US FDA approval for Covid-19 antibody drug

    May 27, 2021

    GSK granted US FDA approval for Covid-19 antibody drug

  • Top shareholders offer support to GSK following activist hedge fund investment

    May 17, 2021

    Several of GlaxoSmithKline’s top shareholders have contacted its chairman to offer support, following concerns activist hedge fund Elliott Management is preparing to push for a shake-up at the group. Shareholders including BlackRock, Dodge & Cox and Royal London are said to have given their support, the Times first reported. The pharma giant has come under [...]

  • GSK profit drops sharply due to pandemic but beats forecasts

    April 28, 2021

    Pharma giant GSK saw its profit and turnover slip in the first quarter due to the impact of the coronavirus pandemic, but came in ahead of analyst expectations. The FTSE 100 firm said that adjusted operating profit fell 30 per cent in the period, down to £1.9bn. Turnover slid 18 per cent to £7.4bn, it [...]

  • GlaxoSmithKline share price leaps at news of activist hedge fund interest

    April 16, 2021

    Shares in GlaxoSmithKline continued to rise on Friday after it emerged that activist hedge fund Elliot Management had built a large stake in the company. New York-based firm Elliot Management, run by billionaire Paul Singer, is believed to have made the multibillion-pound investment earlier this week. GSK was one of the FTSE 100’s biggest risers [...]

  • The week ahead, 1-5 February: FTSE heavyweights front up to third lockdown

    January 31, 2021

    After a turbulent opening to 2021, with new Covid-19 lockdowns around the world, spats over “vaccine nationalism”, and chaos on both Wall Street and Pennsylvania Avenue, a slew of FTSE heavyweights are set to update the market in what will be a crunch week for London’s indices. Despite a strong opening week, the FTSE 100 [...]

  • Asian consumers, boomerang businesses and M&A likely to shape 2021

    January 6, 2021

    It was some year. Anyone who took on the challenge of forecasting what would happen in 2020 more than likely saw it all swiftly swept aside – but, as they say, prediction is very difficult, especially when it’s about the future.  Still, investing is a forward-looking profession and so we inevitably find ourselves thinking about [...]

  • How close are we to having an approved coronavirus vaccine?

    October 28, 2020

    There are a number of vaccine programmes which have advanced to stage three trials, the final hurdle before approval, including two based in the UK. How are they progressing?

  • GSK profit falls a fifth in the third quarter

    October 28, 2020

    Glaxosmithkline (GSK) saw profit attributable to shareholders slip nearly a fifth in the third quarter, but said it was on track to deliver on its guidance for the year. The update came after the pharma giant announced that it would provide a global coronavirus vaccine programme with 200m doses of its candidate. Over the three [...]

  • GSK and Sanofi begin human trials of coronavirus vaccine

    September 3, 2020

    Glaxosmithkline (GSK) has today announced that it is beginning human trials of the coronavirus vaccine it is developing with French pharma firm Sanofi. The two joined forces back in April to develop the potential vaccine, testing of which is now ready to move to the next stage after promising initial results. The combined phase 1 [...]

  • GSK sales fall as vaccine demand slumps during lockdown

    July 29, 2020

    Revenue at drugs giant Glaxosmithkline (GSK) fell below analyst expectations today as sales of its blockbuster Shingles vaccine contracted sharply in the second quarter. Turnover dropped three per cent to £7.6bn, a little below forecasts of £7.7bn, while earnings per share fell back to 19.2p, lower than the 20.1p predicted. Shares in the FTSE 100 [...]

Posts pagination

  • Previous
  • Page 1
  • …
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • …
  • Page 22
  • Next

Trending Articles

  • Nottingham Forest owner Marinakis sues Crystal Palace for defamation

  • Back to basics: Sainsbury’s gradual retreat from the British high street

  • Hargreaves Lansdown orders staff back to office

  • As it happened: Intel, Arm shares slide; Oil climbs higher

  • Thames Water faces fresh threat to survival after pensions regulation breach

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook